The company will grant underwriters a 30-day option to purchase additional shares of common stock. All shares are being offered by Conformis.
The company said it will use any proceeds to fund research and development and sales and marketing costs, clinical studies, manufacturing development, potential acquisitions and repayment or refinance of debt.
Conformis has not priced the offering.
More articles on practice management:
How key spine trends are shaping up in 2021
What hospitals in 10 cities charge for a common spine surgery
Rothman Orthopaedics CEO to retire after 22 years
